Detection and reporting of RB1 promoter hypermethylation in diagnostic screening

Ophthalmic Genetics
Elizabeth A PriceZerrin Onadim

Abstract

RB1 gene screening aids clinical management and genetic counselling in retinoblastoma families. Here we present epigenetic changes identified during routine molecular RB1 screening of tumor and blood samples. Complications in interpreting RB1 methylation are discussed. Screening for RB1 promoter hypermethylation was carried out by Methylation Specific PCR (MS-PCR) after bisulphite modification of DNA. The cohort consisted of 315 tumors, and 204 blood samples, from 497 retinoblastoma patients (22 patients had both blood and tumor screened). 11.4% of retinoblastoma tumors had promoter hypermethylation. It was not routinely detected in blood samples, or in tumors with two other oncogenic RB1 changes. One blood sample had promoter hypermethylation due to an X;13 translocation. One tumor had low level methylation as well as two other oncogenic changes. Histopathological analysis of a small subset of age-matched tumors was similar regardless of promoter hypermethylation status. Promoter hypermethylation was detected in 11.4% of the retinoblastoma tumors and should be tested for in routine RB1 screening programmes. Constitutional samples are not expected to display RB1 hypermethylation. In a small proportion of cases it may not be pos...Continue Reading

References

Jul 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·Z OnadimJ K Cowell
Oct 1, 1994·Human Genetics·D R LohmannB Horsthemke
Aug 11, 1994·Nucleic Acids Research·S J ClarkM Frommer
Oct 6, 1997·Cancer Genetics and Cytogenetics·N Ohtani-FujitaT Sakai
Feb 11, 1999·American Journal of Human Genetics·M KlutzD R Lohmann
Jan 17, 2004·Cancer Biology & Therapy·Biju JosephGovindasamy Kumaramanickavel
Jan 24, 2013·Briefings in Functional Genomics·Duncan Sproul, Richard R Meehan
Nov 15, 2013·Journal of Medical Genetics·Elizabeth A PriceZerrin Onadim
Nov 28, 2013·PloS One·Deniz KanberDietmar Lohmann
Feb 11, 2014·Oncotarget·Justina McEvoyMichael A Dyer
Apr 2, 2014·Journal of Medical Genetics·Charlotte J DommeringAnnemarie H van der Hout

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Related Papers

Journal of Medical Genetics
Elizabeth A PriceZerrin Onadim
Medycyna wieku rozwojowego
E Kostyk, J J Pietrzyk
Methods in Molecular Biology
Thaís M McCormick, Maria Da Glória Da C Carvalho
© 2022 Meta ULC. All rights reserved